Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis
about
A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary cultureα2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.Organization of the human alpha 2-plasmin inhibitor geneNoncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence.The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinaseFunctional factor XIII-A is exposed on the stimulated platelet surfaceThe effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplaseImpact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague.Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell linesAspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activityPlasminogen interacts with human platelets through two distinct mechanismsCatabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin.Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factorIdentification of a specific receptor for plasmin on a group A streptococcus.Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency.Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis.Full time course kinetics of the streptokinase-plasminogen activation pathway.Inhibitory spectrum of alpha 2-plasmin inhibitor.Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors.The behavior of alpha2-plasmin inhibitor in fibrinolytic states.Plasmin inhibitor interactions. The effectiveness of alpha2-plasmin inhibitor in the presence of alpha2-macroglobulin.Physiological activation of plasminogen in full term newborn infantsKinetic properties of the primary inhibitor of plasmin from human plasma.Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma.Natural anticoagulant mechanisms.Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of alpha 2-plasmin inhibitorPartial purification and characterization of a new fast-acting plasmin inhibitor from human platelets. Evidence for non-identity with the known plasma proteinase inhibitorsAlpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.Complex-formation and inhibition of urokinase by blood plasma proteins.Affinity-chromatographic purification of human alpha 2-antiplasmin.alpha-2-antiplasmin + plasmin -> alpha-2-antiplasmin:plasmin
P2860
Q28571160-27764D94-0365-49A3-91BB-2B6733312D8AQ30248728-EAF1005D-4E3C-458B-ADF0-00D1B8EBE132Q33648214-C8066F7E-DA64-4183-A55D-DBCA0B5E5257Q34101596-CB8BB9BC-2049-42AF-824D-C4C008E65DF9Q34529594-E4836107-C1C5-42F8-A81C-7ED63FDFD227Q34572566-8B6011E2-4A0B-45D6-B0A5-C04D82A4A15BQ34630896-52C41057-4417-48B7-827E-11713260044DQ35023065-8CA28080-43B0-4F65-9DCE-87206846E1EFQ35624598-7B486D79-93CD-4AD3-A10F-3447CA11CFDFQ36281274-6151EA50-4829-453C-BD27-D2BFA9296263Q36312684-6FA191A5-05B6-4F38-A953-4E8388054937Q36993272-F56C1576-F239-4113-8689-9FA4816169DEQ36994814-411FCD9F-5F8D-4393-9B16-47DC007CB795Q37016303-5B229AEE-1FE7-4112-A48E-E9881B243602Q37020020-EB17BB47-686F-4EA3-BBEE-4A7A893F576EQ37021903-2C08D4C1-9B0D-44CD-9D06-3589F50BBBABQ37038122-FFBC8C8A-12FF-4D4B-8CEF-F99C40C2C1CFQ37053493-F3E2D10A-93ED-4977-8C5F-953D51B84FAFQ37226126-93647260-18E6-4530-9AF8-A9DE5D7000C7Q37328778-B77E8A1A-5346-4E14-8BB7-6D7C6D8228E0Q37687654-E84E3259-347F-4E75-B675-E43E1817D06DQ38704015-FE3ECED1-DB06-4A66-A8E1-E995D3512ACAQ39441547-1C5E5A5B-D8F8-4755-AA84-BAFB7104E560Q39449655-55A77615-1927-4D53-AE98-59A5E0C5D1EFQ39535698-CD46E022-CA2E-414B-89F2-40A0D9EF3A09Q39817381-9E485E97-49D7-4FBA-842C-74C68A0E8C17Q39876667-09EE437C-D047-4D28-B3F5-C470F04B244FQ40143046-07DAA212-A0A2-46E7-B142-5E9082662B4DQ40304011-452386CD-1639-4B7F-9AAA-7DDE9CAE250DQ40683743-04847D57-1537-4402-A12F-BDA58444382FQ40684825-6487DDFF-0CF6-418B-8074-E3035B3E3F05Q41476888-3B869B42-E0E2-466F-A714-7899FEB42632Q41822745-7C6615D4-CB62-4F59-BF9D-B5CB56EF94A8Q41899454-330581D0-E2AA-4818-9F9A-D0005394740FQ41981370-34E33DE7-2ED8-4835-A811-D442D11EF9DBQ42127015-B9AC1F4D-D084-4CB4-9BEB-330DD3C3449DQ42848184-E0AC3367-B468-4DAA-A7B2-1C78F21BF0D2Q42865484-7206DA24-F861-4842-8CC1-2BB78B6E5238Q42881636-E823EA99-406E-44FC-8B57-5742AA21403EQ50291250-61C82736-03CE-4B71-800B-2DCDAF2DB7F8
P2860
Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis
description
1976 nî lūn-bûn
@nan
1976 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
Isolation and characterization ...... s activator-induced clot lysis
@ast
Isolation and characterization ...... s activator-induced clot lysis
@en
Isolation and characterization ...... s activator-induced clot lysis
@en-gb
Isolation and characterization ...... s activator-induced clot lysis
@nl
type
label
Isolation and characterization ...... s activator-induced clot lysis
@ast
Isolation and characterization ...... s activator-induced clot lysis
@en
Isolation and characterization ...... s activator-induced clot lysis
@en-gb
Isolation and characterization ...... s activator-induced clot lysis
@nl
prefLabel
Isolation and characterization ...... s activator-induced clot lysis
@ast
Isolation and characterization ...... s activator-induced clot lysis
@en
Isolation and characterization ...... s activator-induced clot lysis
@en-gb
Isolation and characterization ...... s activator-induced clot lysis
@nl
P1476
Isolation and characterization ...... s activator-induced clot lysis
@en
P304
P407
P577
1976-10-10T00:00:00Z